Paper
COMPUTATIONAL AND PHARMACOLOGICAL EVALUATION OF HETEROCYCLIC 1,3,4-OXADIAZOLE AND PYRAZOLES NOVEL DERIVATIVES FOR TOXICITY ASSESSMENT, TUMOUR INHIBITION, ANTIOXIDANT, ANALGESIC AND ANTI-INFLAMMATORY ACTIONS
Published Oct 13, 2018 · M. Faheem
FARMACIA
12
Citations
1
Influential Citations
Abstract
The present research work was focused on the computational and pharmacological potential of 1,3,4-oxadiazole and pyrazole novel derivatives including: N-{4-[(5-sulfanyl-1,3,4-oxadiazol-2-yl)methoxy]phenyl acetamide (a3), 5-[(naphthalen-2-yloxy) methyl]1,3,4-oxadiazole-2-thiol (b3), 3-phenyl-5-(o-hydroxyphenyl)-1-[2-(p-N-acetylaminophenoxyacetylpyrazole (a6) and 3phenyl-5-(o-hydroxy phenyl)-1-[2-(2’-naphthyloxy)acetyl] pyrazole (b6). Docking against targets including epidermal growth factor receptor (EGFR), tubulin, cyclooxygenase-2 (COX-2) and 5-lypoxygenase (5-LOX) were followed by the investigation of a3, b3, a6, and b6 for toxicity, tumour inhibition, free radical scavenging, analgesic and anti-inflammatory potential. Compound a3 showed binding and moderate inhibitory effects in all assays, b3 possess good affinity for COX-2 and 5-LOX which can be correlated to its highest analgesic and anti-inflammatory effects. Compound a6 showed binding to all targets and antioxidant potential, with an EC50 value of 100 μg/mL, b6 formed two hydrogen bonds with tubulin and was the most potent in the toxicity assessment and tumour inhibition with LC50 values of 2.47 and 5.51 μg/mL respectively.
Novel 1,3,4-oxadiazole and pyrazole derivatives show potential for toxicity assessment, tumor inhibition, antioxidant, analgesic, and anti-inflammatory effects.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...